key: cord-0756164-hh5rg65l authors: Yang, H. S.; Racine-Brzostek, S. E.; Karbaschi, M.; Yee, J.; Dillard, A.; Steel, P. A. D.; Lee, W. S.; McDonough, K. A.; Qiu, Y.; Ketas, T. J.; Francomano, E.; Klasse, P. J.; Hatem, L.; Westblade, L. F.; Wu, H.; Chen, H.; Zuk, R.; Tan, H.; Girardin, R.; Dupuis, A. P.; Payne, A. F.; Moore, J. P.; Cushing, M. M.; Chadburn, A.; Zhao, Z. title: Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients date: 2020-11-22 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.11.19.20235044 sha: cb55261d98ba7f59e0a4465cb68d6a71c6573b1f doc_id: 756164 cord_uid: hh5rg65l The association of mortality with early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS) has not been thoroughly investigated partly due to a lack of sufficiently sensitive antibody testing methods. Here we report two sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2 viral specific total antibodies (TAb) and surrogate neutralizing antibodies (SNAb), which are suitable for clinical use. The TOP assays employ an RBD-coated quartz probe using a Cy5-Streptavidin-polysacharide conjugate to improved sensitivity and minimize interference. Disposable cartridge containing pre-dispensed reagents requires no liquid manipulation or fluidics during testing. The TOP-TAb assay exhibited higher sensitivity in the 0-7 DAOS window than a widely used FDA-EUA assay. The rapid (18 min) and automated TOP-SNAb correlated well with two well-established SARS-CoV-2 virus neutralization tests. The clinical utility of the TOP assays was demonstrated by evaluating early antibody responses in 120 SARS-CoV-2 RT-PCR positive adult hospitalized patients. Higher baseline TAb and SNAb positivity rates and more robust antibody responses were seen in patients who survived COVID-19 than those who died in the hospital. Survival analysis using the Cox Proportional Hazards Model showed that patients who were TAb and SNAb negative at initial hospital presentation were at a higher risk of in-hospital mortality. Furthermore, TAb and SNAb levels at presentation were inversely associated with SARS-CoV-2 viral load based on concurrent RT-PCR testing. Overall, the sensitive and automated TAb and SNAb assays allow detection of early SARS-CoV-2 antibodies which associate with mortality. Ten months after the emergence of Coronavirus Disease 2019 and the identification of more than 40 million confirmed cases (Dong et al. 2020 ), many clinical and biologic aspects of the disease are not yet understood (Callaway et al. 2020) . It is unknown why the initial clinical presentation does not necessarily correlate with subsequent disease severity and why some patients, even those who are young or are without significant co-morbidities, die from COVID-19 whereas others recover. Analyses of risk factors for a poor outcome in hospitalized COVID-19 patients Ruan et al. 2020; Wolff et al. 2020; Zheng et al. 2020 ) have largely focused on patient clinical presentation, demographics, comorbidities, and non-specific laboratory testing results (Wiersinga et al. 2020 ). However, COVID-19 serologic assays that evaluate patient humoral response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more disease specific and thus are likely to correlate better with disease severity and/or survival (Klasse and Moore 2020) . While many studies have reported that the magnitude of antibody response to SARS-CoV-2 tracks with the severity of COVID-19, these differences are generally seen more than 2-3 weeks after the onset of symptoms (Long et al. 2020; Lynch KL 2020; Yang et al. 2020; . Variations in the early humoral immune response to SARS-CoV-2, which may be more predictive of clinical outcome, have not been thoroughly investigated, due at least in part, to the lack of serologic testing methods that are sufficiently sensitive during the key early days of infection Yang et al. 2020) . Moreover, few studies have focused on the association of early antibody response and patient outcome, including mortality ). Most neutralizing antibodies (NAbs) against SARS-CoV-2 block the receptor-binding domain (RBD) of the spike (S) glycoprotein from interacting with human angiotensin-converting enzyme All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 5 2 (ACE2), thereby preventing virus entry the host cell (Ju et al. 2020) . The presence of NAbs early after infection may be important in avoiding severe disease manifestations by limiting the number of host cells that become productively infected. However, measuring SARS-CoV-2 NAb activity during the acute phase of COVID-19 is difficult for clinical laboratories; the assays often require specialized equipment and are labor intensive, time consuming (4 days) procedures, and hence throughput is low. For instance, the conventional virus neutralization test requires biosafety level (BSL)-3 containment facilities for handling live virus and takes several days to complete (Lee WT 2020) . Although the pseudovirus neutralization test and ELISA-based surrogate neutralization assays can be performed in the more widely available BSL-2 laboratories, they are still labor intensive and time consuming , and hence problematic for generating real time results in the clinical arena. In this study, we developed two rapid, sensitive and fully automated testing-on-a-probe (TOP) assays to detect and quantify: i) total SARS-CoV-2 antibodies (TAb); and, ii) surrogate neutralizing antibodies (SNAb) that inhibit RBD-ACE2 interactions. The TOP assay employs a receptor-binding domain (RBD)-coated quartz tip biosensor with Cy5-Streptavidinpolysaccharide (Cy5-SA-PS) conjugate, which facilitates the capture of target molecules, minimizes the effect of any interfering substances in the serum and enhances the signal intensity. We then performed analytical and clinical validation of the TOP assays. The clinical utility of these novel assays was further investigated to explore whether the timing and magnitude of the SARS-CoV-2 antibody response are associated with COVID-19 mortality. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 doi: medRxiv preprint 6 2. Experimental methods: The sensitivity of the new assays is enhanced by improving the conjugation chemistry to increase the binding signal and minimizing the non-specific binding. Details are described in the Supplemental Materials. The TOP-TAb assay measures the overall binding between SARS-CoV-2 antibodies and the receptor-binding domain (RBD) of the virus spike (S) protein ( Figure 1A) . The assay is comprised of RBD pre-coated probes and preloaded reagent strips. To construct the biosensor probe, silane treated hydrophobic glass pins were coated with recombinant SARS-CoV-2 RBD protein (Sino Biological, Beijing, China). Biosensor probes were then exposed to PBS with 15% sucrose, as a preservative, and dried in an oven for 30 minutes at 40ºC. Strips were constructed of biotinylated RBD using EZ-Link NHS-LC-LC-Biotin (Thermo Fisher Scientific, Waltham, MA, USA) and Cy5-SA-PS conjugate. Finally, probes and strips were assembled together as a single cartridge (ET Healthcare, Palo Alto, CA). The TAb assay is fully automated on the Pylon 3D analyzer (ET Healthcare). The instrument's pipetting system dilutes the patient sample (26 µL) in PBS (1:5) and dispenses the diluted the solution into a microwell. The instrument probe is moved through sequential incubations in a series of wells containing diluted patient sample, biotinylated RBD and finally the Cy5-SA-PS conjugate. After each incubation, the instrument carries out a brief wash sequence. The instrument detects the fluorescence of the B-RBD/Cy5-SA bound on the probe tip using a builtin optical system as the last step of the assay. The total assay time is 16 min. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 Designed as a competitive binding assay, the TOP-SNAb (Figure 1B) , is based on the anti-SARS-CoV-2 antibody-mediated inhibition of the interaction between the ACE2 receptor protein and the RBD. The SNAb assay is also fully automated and can be performed using the same instrument as TAb. The assay readout is the percentage of RBD-ACE2 binding, which inversely correlates with the SNAb binding inhibition (neutralizing activity) as described by another SNAb assay (Tan et al. 2020) . The percentage of RBD-ACE2 binding is defined as %B/B0 = (sample RFU/negative control RFU) *100%. The SNAb instrument pipette mixes the patient sample (26 µL) with a biotinylated ACE2 reagent (SinoBiological, 10108-H08H-B) in a well, after which a RBD pre-coated biosensor probe (as described for the TAb assay) is transferred to the well containing the patient sample and biotinylated ACE2 mixture. Following a 12 minute incubation, the instrument transfers the RBD probe to the well containing Cy5-SA-PS. After each incubation, the instrument carries out a brief wash sequence of 15 seconds. The instrument then detects the fluorescence of biotinylated ACE2/Cy5-SA bound on the probe tip and reports it as previously described. The total assay time is 18 min. The Roche Elecsys Anti-SARS-CoV-2 assay (Roche TAb; Roche Diagnostics, Indianapolis, IN) was performed on the Roche Cobas e411 (Roche Diagnostics). This assay received Emergency Use Authorization (EUA) approval from the United States Food and Drug Administration (FDA) and was used for comparison with the TOP-TAb assay. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 The PRNT assay detects viral specific antibodies based on their ability to neutralize their cognate viral infections in Vero E6 cells (C1008, ATCC CRL-1586) (Lee WT 2020) . The PsV assay detects neutralizing antibodies based on their ability to inhibit the entry of SARS-CoV-2 pseudovirus into 293T/ACE2cl.22 cells (obtained from Paul Bieniasz, The Rockefeller University, New York) ). The PsV assay was performed as described previously ) with minor modifications. The titers of PRNT and PsV were reported as PRNT 50 and the half maximal inhibitory concentration (IC50), respectively. The details of these two NAb assays are described in the Supplementary Materials. SARS-CoV-2 RT-PCR testing was performed as part of routine patient care at the time of the patient's emergency department (ED) visit on the Cobas 6800 RT-PCR system (Roche Molecular Systems, Inc., Branchburg, NJ), an assay which received EUA approval from the FDA. The SARS-CoV-2-specific target, ORF1ab, is amplified in this assay and the C T values were obtained for each patient's RT-PCR result. The C T value represents the number of replication cycles required for sufficient gene amplification to produce a fluorescent signal that crosses a predefined threshold. Analysis of C T values has been previously described (Magleby et al. 2020a ). For analysis purposes, patients were categorized into one of three cohorts, based on All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint quantitative C T values: high viral load (C T <25), medium viral load (C T 25-30), and low viral load (C T >30) based on the previous analysis from our institution (Magleby et al. 2020a ). The clinical study was approved by the Institutional Review Board (#20-03021671) of Weill Cornell Medicine (WCM) with a waiver of informed consent. Neutralizing antibody testing at the Wadsworth Center was done under a declared Public Health Emergency with a waiver from the NYSDOH Institutional Review Board. The retrospective clinical study included a primary study cohort of 120 adult patients who presented to the ED and were subsequently hospitalized at NewYork Presbyterian/Weill Cornell Medical Center (NYP/WCMC) from March 8 to April 7, 2020 ( Table 1) . All patients had a nasopharyngeal swab sample that tested positive by SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) within one day of their ED visit. All 120 patients had a serum sample collected within one day of the initial hospital presentation for SARS-CoV-2 antibody analysis. Clinical data collected from the electronic medical record (Allscripts, Chicago, IL) included demographic information, estimated date of symptom onset, presenting symptoms (fever, cough, sore throat, shortness of breath, chest pain, diarrhea, headache, nausea, vomiting, body or muscle aches, fatigue/weakness, ageusia, anosmia, abdominal pain, rhinitis), comorbidities (cancer, obesity, type 2 diabetes, hypertension, hyperlipidemia, and chronic cardiac diseases), compromised immune status (post-transplant, chemotherapy, radiation and chronic corticosteroid use), SARS-CoV-2 RT-PCR results, intubation status and in-hospital mortality. The last day of study follow-up by chart review was September 6, 2020. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint 3. Results The principles of the fully automated biosensor TOP-TAb and TOP-SNAb assays are illustrated in Figure 1A and B. Cy5-SA-PS showed enhanced sensitivity and reduced background. The Cy5-SA-PS generated up to 20-and 16-times higher fluorescence signal from monoclonal SARS-CoV-2 IgG and IgM, respectively, compared to Cy5-SA. The background fluorescence signal of Cy5-SA-PS was 3-times lower than that of Cy5-SA (Figure 1C and D) . The cutoff values of both methods were determined by the mean plus 6 standard deviation (SD) using pre-COVID-19 samples collected in July 2019 (n = 50 for TAb and n = 20 for SNAb). The cutoff values of TAb and SNAb were 20 RFU and 85% B/B0, respectively. Additional pre-COVID 19 serum samples (n = 163 for TAb and n = 27 for SNAb) collected in July 2019 were tested to validate the specificity, which was 99.4% and 100% for TAb and SNAb, respectively. The imprecision was determined by running the high and low levels of quality control samples 2-5 times per day on 3-5 different days. The imprecision of TAb and SNAb measured by coefficient of variation (CV) was 8% and 12%, respectively. The linearity was performed by serial dilution of high TAb and SNAb samples and at least 5 dilution points were used. Linearity was analyzed by simple linear regression. TAb and SNAb had linearity of 8-7494 RFU (R 2 = 0.98) and 3-96% B/B0 (R 2 = 0.99), respectively (Supplemental Figure 1) . To test the accuracy of the TOP-SNAb assay, we compared SNAb with two other established NAb assays, the plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (PsV), using 46 remnant samples randomly collected from COVID-19 convalescent outpatients. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10. 1101 Data generated in the latter two assays were concordant, with a correlation coefficient (r) of 0.77 (p < 0.0001; Figure 2A ). The percentage of ACE2-RBD binding in the SNAb assay, which is an inverse surrogate for virus-neutralization (SNAb binding inhibition), was then shown to correlate well with both the PRNT (r = -0.82, p < 0.0001) and PsV assays (r = -0.80, p < 0.001) ( Figure 2B and C). As an evaluation of clinical sensitivity, 116 serum samples from 39 patients were analyzed to compare TOP-TAb and TOP-SNAb with a widely used FDA-approved (EUA) total antibody assay (Roche TAb). The detection rates of the three assays during different periods: days after onset of symptoms (DAOS) and days after initial ED presentation (DAED) are shown in Figure 3A and Supplementary Table 1 As expected, the sensitivity of each antibody assay increased substantially at later testing times (> 3 DAED and >7 DAOS); there were no significant differences between the three assays during this later period (Figure 3B and Supplementary Table 1 and 2) . The most prominent advantage of the TOP-TAb and TOP-SNAb assays is their superior ability to detect antibodies in the critical early window from 0-7 DAOS, when patients first present for clinical care. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint To further evaluate the clinical utility of the more sensitive and automated assays within the first few days of infection, TAb and SNAb were measured in SARS-CoV-2 RT-PCR positive patients who had the ED day 0 serum sample collected during their initial hospital presentation. Of the 120 patients, 31.7% (38/120) were intubated and 26.7% (32/120) died during hospitalization. The median DAOS at the time of hospital presentation was 7 days (IQR: 4-10). Demographic, clinical presentation and comorbidity data are shown in Table 1 (stratified by survival status) and Supplementary Table 3 (stratified by intubation status). Intubation, age and cancer were significantly higher in patients who died than the survivors (p < 0.001, Table 1 ). SNAb data were missing in 6 samples due to an insufficient quantity of serum. Patient antibody status in the TAb assay was categorized into positive (signal > 20 IFU, the assay cutoff) and negative (signal ≤ 20 IFU) groups, and similarly for the SNAb assay (positive = %B/B0 ≤ 85%, the assay cutoff; negative = %B/B0 > 85%, see methods section). The TAb positivity rate was significantly higher for the patients who survived (63.6%; 56/88) than for patients who died (34.4%, 11/32, p = 0.007, Figure 4A) . Similarly, the SNAb positivity rate for patients who survived (61.2%, 52/85) was also higher than for those who died (24.1%, 7/29, p = 0.001, Figure 4A) . Furthermore, the TAb levels and SNAb binding inhibition were significantly higher in the patients who survived than who died (p = 0.004 and p = 0.004, respectively, Figure 4B , 4C). In contrast, no significant differences in antibody positivity rates or levels of TAb and SNAb in the initial ED samples were observed when comparing intubation status. However, the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint 13 SNAb positivity rate was lower for patients who were intubated than for those who were not. (p=0.026, Supplementary Figure 2) . Survival analysis was performed using the Cox Proportional Hazards Model adjusted for age and cancer comorbidity, which were two variables showing significant differences between death and survival groups in the univariate analysis (Table 1) . Patients with negative TAb at the time of initial hospital presentation had a higher hazard of in-hospital mortality than those with a positive TAb [hazard ratio (HR) = 2.33 (95% CI: 1.09-5.00, p=0.029), Figure 5A ]; a similar finding was made when the SNAb data were analyzed in the same way [HR = 3.25 (95% CI: 1.33-7.94; p=0.01), Figure 5B ]. To further validate whether TAb and SNAb levels associated with SARS-CoV-2 viral load, the initial nasopharyngeal swab SARS-CoV-2 RT-PCR C T values determined using the Cobas SARS-CoV-2 assay were obtained from 73 of 120 (60.8%) patients. All C T values generated using other RT-PCR assay systems were excluded for consistency. Using a method described elsewhere, the resulting data sets were grouped as follows: high viral load (C T value < 25, n = 21, 28.8%), medium viral load (C T value 25-30, n = 31, 42.5%), low viral load (C T value > 30, n = 21, 28.8%) . TAb (n= 73) and SNAb (n = 68) in samples collected within one day of the RT-PCR testing were compared with the C T values. The analysis showed that the patients with low viral loads (C T > 30) had significantly higher TAb levels than those with the medium (p = 0.017) and low viral loads groups (p=0.004, Figure 4D ), respectively. Similarly, patients with low viral All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint 14 loads (C T > 30) also had higher SNAb binding inhibition than the low viral load group (p = 0.020, Figure 4E ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint In this study, we report that novel TOP-TAb and TOP-SNAb assays can detect SARS-CoV-2 viral specific antibodies early after the onset of symptoms, notably more sensitive than a commonly used SARS-CoV-2 serology assays. The greater sensitivity of these new assays allows for the detection of SARS-CoV-2 antibody responses on the first day of hospital visit that associate with COVID-19 mortality. In this initial care context, the rapidity, simplicity and sensitivity of the TOP assays are all advantages over previous methods. Both TAb and SNAb assays yield results in 16-18 minutes and the instrument is easy to operate in a routine clinical laboratory without the need for BSL-3 containment. The new SNAb assay offers a great opportunity to incorporate the measurement of SNAb into a clinical assessment of patient's risk while the patient is waiting in the ED or a physician's office. The TOP biosensor is a versatile sensing method. Unlike most of other biosensor technologies that transport samples to sensors, the TOP method brings the sensor to a sample to achieve high sensitivity and high precision. Specifically, to test SARS-CoV-2 TAb and SNAb, the TOP assays utilize an RBD-coated quartz tip that moves through microwells on an unitized disposable test strip with pre-dispensed reagents. No reagents are dispensed during the assay procedure eliminating the need for fluid handling subsystems in the instrument. Whole blood, serum and plasma specimens can all be tested using TOP biosensors. The small surface area of the precoated tip (1 mm diameter) allows for small sample volume (26 µL), low reagent consumption and, more importantly, negligible interaction with interference from patient samples. The fluorescence signal is enhanced by a Cy5-SA-PS conjugate. The high-molecular-weight PS serves as an inert carrier of multiple Cy5-SA molecules (~ 30 SAs / PS) and amplifies the signal All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 by approximately 20-fold compared to unconjugated Cy5-SA. Background signal is negligible since the PS is hydrophilic and has minimal interaction with the tip surface. Utilization of TOP with the Cy5-SA-PS conjugate results in an improved signal-to-noise ratio, i.e. high sensitivity, for the detection of SARS-CoV-2 antibodies. Although the TOP assays in this study were not designed to differentiate antibody isotypes and are sensitive to only SARS-CoV-2 RBD or spike protein specific antibodies, the approach described in this study simplifies assays and their development process significantly. New assay development can be readily accomplished by using the same biosensor probe designed to generate signal in response to a specific SARS-CoV-2 antibody isotype and target other SARS-CoV-2 specific antigens. Utilizing the TOP assays, we demonstrate, for the first time, that SARS-CoV-2 TAb and SNAb upon initial presentation are risk indicators for in-hospital mortality, and higher antibody levels are associated with a lower viral load. There has been significant controversy over the antibody response in patients with different levels of COVID-19 disease severity and different outcomes (Klasse and Moore 2020) . Multiple studies have shown that SARS-CoV-2 specific antibody levels, such as IgM, IgG or NAb are elevated in patients with a more severe disease courses (Lynch KL 2020; Wang et al. 2020a; Wang et al. 2020b; Zohar and Alter 2020) . However, a few other publications have reported no significant differences in SARS-CoV-2 antibody responses between severe and non-severe patients (Phipps et al. 2020; Ren et al. 2020 ). These discrepancies could involve a variety of factors, including the patient populations, the definitions of disease severity, the serology assays used, the isotypes of antibody or target epitopes being detected, and the timing in the disease course when the antibody testing is performed. Here, we focused on the association, using the sensitive TOP assays, between TAb All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 17 and SNAb on the first day of hospital visit and subsequent mortality. Our findings are congruent with recent reports that early immunologic protection in COVID-19 patients is important. For instance, Atyeo et al. identified that an early SARS-CoV-2-specific humoral signature profile, including levels of S-specific IgM and IgA, N-specific complement activity, IgM and IgA1, is associated with later disease outcome . Thus, it is reasonable to postulate that if SARS-CoV-2 TAbs and NAbs appear early in the disease process, they may play a protective role directly or indirectly suppressing SARS-CoV-2 replication. Antibody response kinetics may differ in patients who survive versus those who die from COVID-19. For example, patients with low or undetectable levels of SARS-CoV-2 antibodies at an early stage may not be able to suppress the initial phase of virus replication; the resulting seeding of multiple foci of infection could then drive the emergence of high viral loads, which could in turn trigger the production of a much stronger later antibody response. However, these high-titer antibodies may appear too late to prevent severe disease and death. These hypotheses are concordant with our observation that patients with relatively high antibody levels early in the disease progress also had lower SARS-CoV-2 viral loads, particularly as viral load is independently associated with in-hospital mortality (Magleby et al. 2020b; Pujadas et al. 2020; Westblade LF 2020) . The associations between an early antibody response to SARS-CoV-2, initial viral load and eventual in-hospital survival are consistent with strong, early humoral immunity countering SARS-CoV-2 replication in a way that benefits disease control. A recent study of 35,000 hospitalized patients with COVID-19 showed that early transfusion of convalescent plasma (within 3 days of diagnosis) with high antibody levels was associated with reduced mortality (Joyner MJ 2020) . The lack of an association with intubation may reflect the variability and All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 evolution in our intubation practice during the height of the pandemic in New York City (Tobin M.J. 2020) . These findings further argue for the clinical benefits of suppressing SARS-CoV-2 replication via specific antibodies very early during the disease course (i.e., the first week post onset of symptoms). The early identification of high-risk patients, (i.e., those who do not generate early and strong antibody responses of their own) could have significant implications for managing their immediate and future care. We report a novel, rapid, highly sensitive and fully automated biosensor technology (TOP) that is easily adaptable to the clinical laboratory setting. These new assays allow the detection of early SARS-CoV-2 antibodies on the first day of a hospital or clinic visit and show that the levels of SARS-CoV-2 total and functional antibodies are inversely associated with subsequent COVID-19 mortality. Application of our new assays has led to the discovery of new information on the acute humoral immune response to SARS-CoV-2 infection and may have valuable prognostic and treatment implications relevant to patient care. Future studies will explore if these new sensitive and specific assays could potentially monitor the efficacy of antiviral therapies as well as assess antibody responses during vaccine trials. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint 21 Figure 2 . Correlation of the TOP-SNAb assay with two well-established SARS-CoV-2 NAb assays. The correlations between the PsV and PRNT, between TOP-SNAb and PRNT, and between TOP-SNAb and PsV are shown in Figure 2A , B, C, respectively. The readout of TOP-SNAb is the percentage of RBD-ACE2 binding, which inversely correlates with the SNAb binding inhibition (neutralizing activity). The titers of PRNT and PsV were reported as PRNT 50 and IC50, respectively. The results were presented as Log10 scale. Correlations between two assays were assessed by Spearman correlation coefficient. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint 23 positive rates were higher in patients who survived than who died. (B) TAb level and (C) SNAb binding inhibition were higher in patients who survived than who died. Association of (D) TAb and (E) SNAb with SARS-Cov-2 ORF1ab target C T values at the time of hospital ED presentation. Data were expressed as Log10 scale with box and whisker (10-90 percentile) plots. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 24 24 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 Abdominal pain n. (%) 2 (6.2%) 6 (6.8%) >0. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted https://doi.org/10.1101 https://doi.org/10. /2020 Alter, G. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival Six months of coronavirus: the mysteries scientists are still racing to solve An interactive web-based dashboard to track COVID-19 in real time Cater RE, Casadevall A. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial threemonth experience the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization Neutralizing Antibody Responses in COVID-19 Convalescent Sera Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Antibody responses to SARS-CoV-2 in patients with COVID-19 Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease Antibody Responses Do Not Predict COVID-19 Disease Severity SARS-CoV-2 viral load predicts COVID-19 mortality Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post hoc Analysis of LOTUS China Trial All rights reserved. No reuse allowed without permission preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction Clinical Performance of Two SARS-CoV-2 Serologic Assays Caution about early intubation and mechanical ventilation in COVID-19 Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Risk factors for Covid-19 severity and fatality: a structured literature review SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays All rights reserved. No reuse allowed without permission preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis A pneumonia outbreak associated with a new coronavirus of probable bat origin Dissecting antibody-mediated protection against SARS-CoV-2 This research was partially funded by a COVID-19 research grant from Weill Cornell Medicine.PJK, TJK, EF and JPM were supported by NIH grant R01 AI36082. We want to thank Hanna Rennert, Arryn R. Craney, Priya Velu for their effort on RT-PCR method development. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10.1101/2020.11.19.20235044 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this this version posted November 22, 2020. ; https://doi.org/10. 1101